R P Gray1, J S Yudkin, D L Patterson. 1. Department of Medicine, University College London Medical School, Whittington Hospital.
Abstract
OBJECTIVE: To compare the activity of plasminogen activator inhibitor (PAI-1) in diabetic and non-diabetic patients admitted with acute myocardial infarction and to determine whether PAI-1 activity influences reperfusion after thrombolytic therapy. DESIGN: Prospective study of patients admitted with acute myocardial infarction. SETTING: District general hospital. MAIN OUTCOME MEASURES: Reperfusion assessed by time to peak release of creatine kinase-MB isoenzyme. RESULTS: Baseline PAI-1 activity and antigen concentrations were significantly higher in diabetic patients (n = 45) than in non-diabetic patients (n = 110) (24.6 (6.9) v 18.6 (7.9) AU/ml (AU = arbitrary units) (p = 0.0001) and 58.8 (13.1-328.8) v 41.0 (10.9-125.4) ng/ml (p = 0.004). Time to peak release of creatine kinase-MB was calculated in 123 (80%) patients. In 98 who received thrombolytic therapy the median time to peak enzyme release was 15.5 h (7.5-24 h) in diabetic patients (n = 26) and 12 h (5-26 h) in non-diabetic patients (n = 72) (p = 0.005). In those with a time to peak release of < or = 12 h, indicating likely successful reperfusion, PAI-1 activity was 17.5 (7.8) AU/ml compared with 22.8 (7.7) AU/ml in those with a time to peak release of > 12 h (p = 0.001). In multiple regression analysis both diabetes (p = 0.0001) and PAI-1 activity at admission (p = 0.029) were independently related to successful reperfusion. In 13 patients with evidence of reinfarction in hospital PAI-1 activity on day 3 was 26.7 (6.4) AU/ml compared with 21.7 (6.3) AU/ml in those without evidence of reinfarction (p = 0.032). CONCLUSION: Both raised PAI-1 activity on admission and diabetes were associated with a reduced likelihood of enzymatic evidence of reperfusion after thrombolytic therapy. Increased PAI-1 activity on day 3 was associated with an increased risk of reinfarction. Diabetic patients had higher PAI-1 activity on admission. This may partly explain their reduced likelihood of reperfusion.
OBJECTIVE: To compare the activity of plasminogen activator inhibitor (PAI-1) in diabetic and non-diabeticpatients admitted with acute myocardial infarction and to determine whether PAI-1 activity influences reperfusion after thrombolytic therapy. DESIGN: Prospective study of patients admitted with acute myocardial infarction. SETTING: District general hospital. MAIN OUTCOME MEASURES: Reperfusion assessed by time to peak release of creatine kinase-MB isoenzyme. RESULTS: Baseline PAI-1 activity and antigen concentrations were significantly higher in diabeticpatients (n = 45) than in non-diabeticpatients (n = 110) (24.6 (6.9) v 18.6 (7.9) AU/ml (AU = arbitrary units) (p = 0.0001) and 58.8 (13.1-328.8) v 41.0 (10.9-125.4) ng/ml (p = 0.004). Time to peak release of creatine kinase-MB was calculated in 123 (80%) patients. In 98 who received thrombolytic therapy the median time to peak enzyme release was 15.5 h (7.5-24 h) in diabeticpatients (n = 26) and 12 h (5-26 h) in non-diabeticpatients (n = 72) (p = 0.005). In those with a time to peak release of < or = 12 h, indicating likely successful reperfusion, PAI-1 activity was 17.5 (7.8) AU/ml compared with 22.8 (7.7) AU/ml in those with a time to peak release of > 12 h (p = 0.001). In multiple regression analysis both diabetes (p = 0.0001) and PAI-1 activity at admission (p = 0.029) were independently related to successful reperfusion. In 13 patients with evidence of reinfarction in hospital PAI-1 activity on day 3 was 26.7 (6.4) AU/ml compared with 21.7 (6.3) AU/ml in those without evidence of reinfarction (p = 0.032). CONCLUSION: Both raised PAI-1 activity on admission and diabetes were associated with a reduced likelihood of enzymatic evidence of reperfusion after thrombolytic therapy. Increased PAI-1 activity on day 3 was associated with an increased risk of reinfarction. Diabeticpatients had higher PAI-1 activity on admission. This may partly explain their reduced likelihood of reperfusion.
Authors: H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock Journal: N Engl J Med Date: 1987-10-01 Impact factor: 91.245
Authors: Ayman A El Menyar; O M Altamimi; Mohamed M Gomaa; Zainab Fawzy; M O Abdel Rahman; Abdulbari Bener Journal: J Thromb Thrombolysis Date: 2006-06 Impact factor: 2.300
Authors: L F Hsu; K H Mak; K W Lau; L L Sim; C Chan; T H Koh; S C Chuah; R Kam; Z P Ding; W S Teo; Y L Lim Journal: Heart Date: 2002-09 Impact factor: 5.994
Authors: Richard G Jung; Pouya Motazedian; F Daniel Ramirez; Trevor Simard; Pietro Di Santo; Sarah Visintini; Mohammad Ali Faraz; Alisha Labinaz; Young Jung; Benjamin Hibbert Journal: Thromb J Date: 2018-06-05